昭衍新藥(06127.HK)香港公開發售獲310倍認購 上限定價151港元/股
格隆匯 2 月 25日丨昭衍新藥(06127.HK)發佈公吿，公司全球發售4332.48萬股股份，其中香港發售股份1559.7萬股，國際發售股份2772.78萬股，另有15%超額配股權；發售價已釐定為每股發售股份151.00港元，每手買賣單位100股；中信證券為獨家保薦人，預期股份將於2021年2月26日於聯交所主板掛牌上市。
國際發售項下初步提呈的發售股份已獲大幅超額認購，相當於國際發售項下初步可供認購發售股份總數的約26倍。香港公開發售項下初步提呈發售的香港發售股份已獲非常大幅超額認購。合共接獲539,993份有效申請，認購合共12.09億股，相當於香港公開發售項下初步可供認購的香港發售股份總數約310倍。
根據基石投資協議，基石投資者認購的發售股份數目現已確定。Lake Bleu Prime、 Orbimed基金、中國結構調整基金、CPE Fund、Sequoia Capital China Growth、 Janchor Partners Pan-Asian Master Fund、CRF、Carmignac基金、Octagon Capital及Valliance Fund各自已分別認購195.1萬股、179.7萬股、179.7萬股、179.7萬股、154.03萬股、154.03萬股、154.03萬股、102.68萬股、51.34萬股及25.67萬股，合共1375.98萬股發售股份，合共佔緊隨全球發售完成後公司已發行股本約5.1%(假設超額配股權未獲行使且並無計及根據購股權及受限制股份獎勵計劃授出的購股權獲行使後將予發行的任何A股股份)；及全球發售項下的發售股份數目約31.8%(假設超額配股權並無獲行使)。
按發售價每股發售股份151.00港元計算，公司將收取的全球發售所得款項淨額(假設超額配股權並無獲行使)，估計約為62.861億港元。公司擬將全球發售所得款項約16.0%主要用於通過翻新現有設備及設施、建立新的實驗模型繁殖及存貨設施及僱傭經驗豐富的專業人員，用於提高公司蘇州設施的非臨牀研究產能；約10.0%用於增強公司的美國業務以迎合客户對Biomere所提供服務日益增長的需求；約39.0%主要通過在廣州及重慶建設新設施、僱傭經驗豐富的專業人員，及發展尖端技術，用於進一步擴大公司於中國的設施網絡及服務能力；約5.0%用於拓展及深化公司的綜合合同研究組織服務，特別着重於進一步擴展公司的臨牀試驗及相關服務；及約10.0%將用作營運資金及一般企業用途。倘超額配股權獲悉數行使，公司將就超額配股權獲行使後發行最多649.87萬股H股收取所得款項淨額約9.469億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
